Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Saliva-based Detection of CD44

NCT03148665 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to test the ability of OncAlert™ to screen for cancer and the reappearance of cancer. OncAlert™ was developed by Vigilant Biosciences, a collaborator in this research study. OncAlert™ is an oral rinse which is spit into a cup and sent to a laboratory for analysis. OncAlert™ is considered experimental by the FDA because it is not approved for the screening of cancer.

Interventions

  • DEVICE OncAlert

Study Locations (4)

Maryland

  • Greater Baltimore Medical Center — Baltimore
  • Johns Hopkins School of Medicine — Baltimore

California

  • UCSD Moores Cancer Center — La Jolla

New York

  • New York University College of Dentistry — New York

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2017-04-14
Est. Completion 2022-05-03

Sponsor

Joseph Califano

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03148665

The ClinicalTrials.gov registry entry for NCT03148665 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph Califano, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 1 intervention — of which OncAlert is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03148665 reports 4 study locations spanning 3 distinct geographic areas — top geographies include Maryland, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03148665 about?

NCT03148665 is a clinical study titled "Saliva-based Detection of CD44". The purpose of this study is to test the ability of OncAlert™ to screen for cancer and the reappearance of cancer. OncAlert™ was developed by Vigilant Biosciences, a collaborator in this research study. OncAlert™ is an oral rinse which is spit into a cup and sent to a laboratory for analysis. OncAle...

What is the current status of trial NCT03148665?

This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-04-14. Estimated completion is 2022-05-03.

What conditions does trial NCT03148665 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oropharynx. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03148665?

The interventions under investigation include: OncAlert (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03148665?

This trial is sponsored by Joseph Califano, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03148665 being conducted?

This trial has 4 study locations across California, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial